Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival

Abstract

Antiangiogenic therapy using bevacizumab appears to improve survival in patients with recurrent high-grade glioma. A possible change in the invasiveness of the tumor following therapy is worrisome and must be closely monitored.